Trial reportThorax2003
Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD.
Trial report in Thorax, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 224 citations in OpenAlex.
- Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19).Scientific reports · 2022Trial
- Pomegranate juice supplementation in chronic obstructive pulmonary disease: a 5-week randomized, double-blind, placebo-controlled trial.European journal of clinical nutrition · 2006Trial
- Resveratrol for Cancer Radio-Sensitization: Ready for Prime Time or Future Perspective.Food science & nutrition · 2026Review
- Potential role of resveratrol in abdominal cocoon syndrome: targeting inflammation, oxidative stress, and fibrosis via food-derived bioactive compounds resveratrol for treatment of abdominal cocoon syndrome.Frontiers in pharmacology · 2026Review
- Dietary Antioxidant Intake and Sleep Quality: Combined Effects on Chronic Obstructive Pulmonary Disease in NHANES 2005-2008 and Mendelian Randomization Analysis.Food science & nutrition · 2025Article
- Natural Compounds TargetingNutrients · 2025Review
- Pulmonary Emphysema: Current Understanding of Disease Pathogenesis and Therapeutic Approaches.Biomedicines · 2025Review
- Senotherapy for chronic lung disease.Pharmacological reviews · 2025Review
- Nutritional Support of Chronic Obstructive Pulmonary Disease.Nutrients · 2025Review
- Evaluation of the Efficacy of Jiangqi Dingchuan Pill Based on Network Pharmacology Analysis and Cigarette Smoke and Lipopolysaccharide Induced Chronic Obstructive Pulmonary Disease Rat Model.International journal of chronic obstructive pulmonary disease · 2025Article
- Effect of Phytochemical-Rich Food Intake on Respiratory and Muscle Function in Middle-Aged Patients with COPD: A Cross-Sectional Study.Nutrients · 2024Article
- Polyphenols improve non-alcoholic fatty liver disease via gut microbiota: A comprehensive review.Food science & nutrition · 2024Review
- Macrophage Polarization and Functions in Pathogenesis of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2024Review
- Review
- The association between alcohol consumption and pulmonary function: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2024Article
- Resveratrol as sensitizer in colorectal cancer plasticity.Cancer metastasis reviews · 2024Review
- Thrombin-Induced COX-2 Expression and PGEInternational journal of molecular sciences · 2023Article
- Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease.Antioxidants (Basel, Switzerland) · 2023Review
- The Effects of Resveratrol on Silica-Induced Lung Oxidative Stress and Inflammation in Rat.Safety and health at work · 2023Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathophysiology of chronic obstructive pulmonary disease (COPD) features pulmonary inflammation with a predominant alveolar macrophage involvement. Bronchoalveolar macrophages from patients with COPD release increased amounts of inflammatory cytokines in vitro, an effect that is not inhibited by the glucocorticosteroid dexamethasone. Resveratrol (3,5,4'-trihydroxystilbene) is a component of red wine extract that has anti-inflammatory and antioxidant properties. A study was undertaken to determine whether or not resveratrol would inhibit cytokine release in vitro by alveolar macrophages from patients with COPD.
methodsAlveolar macrophages were isolated from bronchoalveolar lavage (BAL) fluid from cigarette smokers and from patients with COPD (n=15 per group). The macrophages were stimulated with either interleukin (IL)-1beta or cigarette smoke media (CSM) to release IL-8 and granulocyte macrophage-colony stimulating factor (GM-CSF). The effect of resveratrol was examined on both basal and stimulated cytokine release.
resultsResveratrol inhibited basal release of IL-8 in smokers and patients with COPD by 94% and 88% respectively, and inhibited GM-CSF release by 79% and 76% respectively. Resveratrol also inhibited stimulated cytokine release. Resveratrol reduced IL-1beta stimulated IL-8 and GM-CSF release in both smokers and COPD patients to below basal levels. In addition, resveratrol inhibited CSM stimulated IL-8 release by 61% and 51% respectively in smokers and COPD patients, and inhibited GM-CSF release by 49% for both subject groups.
conclusionsResveratrol inhibits inflammatory cytokine release from alveolar macrophages in COPD. Resveratrol or similar compounds may be effective pharmacotherapy for macrophage pathophysiology in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.